Next Article in Journal
Impact of Preoperative Yttrium-90 Transarterial Radioembolization on Patients Undergoing Right or Extended Right Hepatectomy for Hepatocellular Carcinoma
Previous Article in Journal
YAP/TAZ Promote GLUT1 Expression and Are Associated with Prognosis in Endometrial Cancer
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers 2025, 17, 1168

1
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, 40138 Bologna, Italy
2
Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, 40138 Bologna, Italy
3
Divisione di Ematologia, Azienda Ospedaliero-Universitaria Policlinico di Catania, Scuola di Specializzazione in Ematologia dell’università di Catania, 95125 Catania, Italy
4
Divisione di Ematologia 1, AOU Città Della Salute e Della Scienza di Torino, 10126 Torino, Italy
5
Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università degli Studi di Torino, 10126 Torino, Italy
6
Unit of Hematology and Stem Cell Transplantation, Department of Precision and Regenerative Medicine and Ionian Area, “Aldo Moro” University School of Medicine, AOUC Policlinico, 70124 Bari, Italy
7
Clinica di Ematologia, Unità di Trapianto di Cellule Staminali e Terapia Cellulare dell’AOU delle Marche, 60126 Ancona, Italy
8
Ematologia, Azienda Ospedaliera Universitaria Policlinico Umberto I, 00161 Roma, Italy
9
Unità di Ematologia, Dipartimento di Medicina (DIMED), Università di Padova, 65100 Padova, Italy
*
Author to whom correspondence should be addressed.
Cancers 2025, 17(15), 2555; https://doi.org/10.3390/cancers17152555 (registering DOI)
Submission received: 27 June 2025 / Accepted: 30 June 2025 / Published: 1 August 2025
(This article belongs to the Section Cancer Therapy)

Affiliations

The authors have separated the affiliations originally listed in affiliation 4—this is so both affiliations can be organized from subordinate to superior.

References

In the original publication [1], there was a mistake, not attributable to the authors, in the order of the bibliographical references. With this correction, the order of some references in the text and tables has been corrected and aligned with the list of references at the end of the manuscript.

Tables

In the original publication [1], the titles and contents of Tables 1 and 2 were not up-to-date with the final version of the manuscript, as requested by the Authors. The corrected tables “Table 1. Currently licensed treatment strategies in len-refractory MM: data on clinical efficacy” and “Table 2. ADC-based triplet treatments for len-refractory MM currently under EMA evaluation: data on clinical efficacy” appear below.

Text Correction

There was text correction made to the following sentence in Section 2—‘In a study aimed at gaining insights into the different patterns of len resistance, a longer exposure (≥1 year) to len and longer interval (≥18 months) from last len dose to subsequent start of pomalidomide were associated with higher response rates and longer PFS and OS, highlighting the importance of optimal sequencing to face the challenge of IMiD refractoriness [5]’.
The subheading for Section 4.1 has been updated to ‘PI-Based Doublets and Triplets Incorporating Either an Anti-CD38 MoAb or an Inhibitor of Exportin 1’.
In Section 4.2 there has been a text correction to paragraph 4—‘The combinations of Pd with MoAbs targeting CD38 and SLAMF7, like isa or elo (i.e., isa-Pd and elo-Pd, respectively), may be considered in heavily pretreated patients’.
There has been a text correction to Section 5, paragraph 5—‘Notably, at the second interim analysis, mOS was not yet reached in both arms, and 36-month estimations of OS were 74% in the BVd group and 60% in the DVd group, suggesting an early and statistically significant benefit with BVd (the HR was 0.58 [95% CI, 0.43–0.79]) [79]’.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Mancuso, K.; Barbato, S.; Di Raimondo, F.; Gay, F.; Musto, P.; Offidani, M.; Petrucci, M.T.; Zamagni, E.; Zambello, R.; Cavo, M. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers 2025, 17, 1168. [Google Scholar] [CrossRef] [PubMed]
Table 1. Currently licensed treatment strategies in len-refractory MM: data on clinical efficacy.
Table 1. Currently licensed treatment strategies in len-refractory MM: data on clinical efficacy.
PI-Based Regimens
OverallLen-Refractory
Study
[Ref]
RegimensPrior LOTs
(m)
mFU
(mos)
mPFS
(mos)
mOS
(mos)
ORR
(%)
≥CR
(%)
MRD-
(%)
Len-Ref
(%)
mPFS
(mos)
mOS
(mos)
ORR
(%)
≥CR
(%)
MRD-
(%)
ENDEAVOR
[30–32]
Kd56 vs. Vd2
(1–3)
44.318.7 vs. 9.447.8 vs. 38.8
(51.3 vs. 43.7 as 2nd LOT)
77 vs. 6313 vs. 6/258.6 vs. 6.629.2 vs. 21.4/15.5 (Kd56)/
CASTOR
[33–35]
DVd vs. Vd2
(1–9)
72.616.7 vs. 7.1
(27.0 vs. 7.9
as 2nd LOT)
49.6 vs. 38.584 vs. 6329 vs. 1014 vs. 2247.8 vs. 4.9////
CANDOR
[36–38]
DKd vs. Kd2
(1–5)
50.628.4 vs. 15.2 50.8 vs. 43.684 vs. 7322 vs. 828 vs. 932 vs. 3628.1 vs. 11.1NR vs. 38.279.8 (DKd)//
IKEMA
[39–44]
isaKd vs. Kd2
(1–4)
56.635.7 vs. 19.2NR vs. 50.687 vs. 8444 vs. 2934 vs. 1532 vs. 34HR 0.60
in favor of isaKd
//39 vs. 1225 vs. 10
BOSTON
[45,46]
SVd vs. Vd2
(1–3)
2813.2 vs. 9.5
(21.0 vs. 10.7
as 2nd LOT)
36.7 vs. 32.8
(NR vs. 32.8 as 2nd LOT)
76 vs. 6217 vs. 11/37 vs. 3910.2 vs. 7.126.7 vs. 18.667.9 vs. 47.2//
IMiD-based regimens
OverallLen-Refractory
Study
[Ref]
RegimensPrior LOTs
(m)
mFU
(mos)
mPFS
(mos)
mOS
(mos)
ORR
(%)
≥CR
(%)
MRD-
(%)
Len-ref
(%)
mPFS
(mos)
mOS
(mos)
ORR
(%)
≥CR
(%)
MRD-
(%)
OPTIMISMM
[47–49]
PVd vs. Vd2
(1–3)
64.511.7 vs. 6.9
(20.73 vs. 11.63
as 2nd LOT)
35.6 vs. 31.682 vs. 5013 vs. 3/71 vs. 6917.8 vs. 9.5
(2nd LOT)
29.8 vs. 24.285.9 vs. 50.8//
APOLLO
[50–52]
DPd vs. Pd2
(1–5)
39.612.4 vs. 6.934.4 vs. 23.769 vs. 4625 vs. 49 vs. 263 vs. 739.9 vs. 6.5////
MM-014
[53,54]
DPd2
(1–2)
41.923.756.778.626.8/7623.053.677.622.4/
ICARIA
[55–58]
isaPd vs. Pd3
(2–4)
52.411.5 vs. 6.524.6 vs. 17.760 vs. 359 vs. 2/94 vs. 92/22.7 vs. 17.5///
ELOQUENT-3
[59]
eloPd vs. Pd3
(2–8)
4510.3 vs. 4.729.8 vs. 17.453 vs. 2620 vs. 9/90 vs. 84/////
CAR-T-based regimens
OverallLen-Refractory
Study
[Ref]
RegimensPrior LOTs
(m)
mFU
(mos)
mPFS
(mos)
mOS
(mos)
ORR
(%)
≥CR
(%)
MRD-
(%)
Len-Ref
(%)
mPFS
(mos)
mOS
(mos)
ORR
(%)
≥CR
(%)
MRD-
(%)
CARTITUDE-4
[60,61]
cilta-cel
vs. SOC
2
(1–3)
33.6NR
vs. 11.8
(30-mos PFS:
59.4% vs. 25.7%)
NR
(30-mos OS: 76.4% vs. 63.8%)
85 vs. 6777 vs. 2462 vs. 19 (ITT)
89 vs. 38 (MRD evaluable pts)
All/////
KarMMa-3
[62,63]
ide-cel
vs. SOC
6
(3–16)
30.913.8 vs. 4.441.4 vs. 37.971 vs. 4244 vs. 635 vs. 273 vs. 79/////
Abbreviations: CR = complete response; DKd = daratumumab + carfilzomib + dexamethasone; DPd = daratumumab + pomalidomide + dexamethasone; DVd = daratumumab + bortezomib + dexamethasone; eloPd = elotuzumab + pomalidomide + dexamethasone; HR = hazard ratio; isaKd = isatuximab + carfilzomib + dexamethasone; isaPd = isatuximab + pomalidomide + dexamethasone; Kd = + carfilzomib + dexamethasone; Kd56 = + carfilzomib (56 mg/m2) + dexamethasone; len-ref = lenalidomide refractory patients; LOT = line(s) of therapy; m = median; mFU = median follow up; mOS = median overall survival; mPFS = median progression-free survival; MRD- = minimal residual disease negativity (10−5 sensitivity level); mos = months; NR = not reached; ORR = overall response rate; Pd = pomalidomide + dexamethasone; PVd = pomalidomide + bortezomib + dexamethasone; Ref = references; SOC = standard of care; SVd = selinexor + bortezomib + dexamethasone; Vd = bortezomib + dexamethasone.
Table 2. ADC-based triplet treatments for len-refractory MM currently under EMA evaluation: data on clinical efficacy.
Table 2. ADC-based triplet treatments for len-refractory MM currently under EMA evaluation: data on clinical efficacy.
OverallLen-Refractory
Study
[Ref]
RegimenPrior LOTs
(m)
mFU
(mos)
mPFS
(mos)
mOS
(mos)
ORR
(%)
≥CR
(%)
MRD-
(%)
Len-Ref
(%)
mPFS
(mos)
mOS
(mos)
ORR
(%)
≥CR
(%)
MRD-
(%)
DREAMM-7
[76–79]
BVd vs. DVd≥139.436.6 vs. 13.4NR in either group
(36-mos OS: 74% vs. 60%)
83 vs. 7134.6 vs. 17.139 vs. 1733 vs. 35
(28 vs. 31
1 prior LOT)
25.0 vs. 8.6/84 vs. 6135 vs. 1142 vs. 13
DREAMM-8
[80,81]
BPd vs. PVd ≥121.8NR vs. 12.7
(NR vs. 18.5 as 2nd LOT)
NR in either group
(12-mos OS: 83% vs. 76%)
77 vs. 7240 vs. 1624 vs. 5 (CR)
32 vs. 5 (VGPR)
81 vs. 7624.0 vs. 9.2
(NR vs. 13.1 as 2nd LOT)
NR in either group
(12-mos OS: 82% vs. 72%)
75 vs. 6838 vs. 1423 vs. 5 (CR)
31 vs. 5 (VGPR)
Abbreviations: BPd = belantamab mafodotin + pomalidomide + dexamethasone; BVd = belantamab mafodotin + bortezomib + dexamethasone; CR = complete response; DVd = daratumumab + bortezomib + dexamethasone; len = lenalidomide; m = median; LOT = line(s) of therapy; mFU = median follow-up; mOS = median overall survival; mPFS = median progression-free survival; MRD- = minimal residual disease negativity (10−5 sensitivity level); mos = months; NR = not reached; ORR = overall response rate; PVd = pomalidomide + bortezomib + dexamethasone; Ref = references; VGPR = very good partial response.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Mancuso, K.; Barbato, S.; Raimondo, F.D.; Gay, F.; Musto, P.; Offidani, M.; Petrucci, M.T.; Zamagni, E.; Zambello, R.; Cavo, M. Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers 2025, 17, 1168. Cancers 2025, 17, 2555. https://doi.org/10.3390/cancers17152555

AMA Style

Mancuso K, Barbato S, Raimondo FD, Gay F, Musto P, Offidani M, Petrucci MT, Zamagni E, Zambello R, Cavo M. Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers 2025, 17, 1168. Cancers. 2025; 17(15):2555. https://doi.org/10.3390/cancers17152555

Chicago/Turabian Style

Mancuso, Katia, Simona Barbato, Francesco Di Raimondo, Francesca Gay, Pellegrino Musto, Massimo Offidani, Maria Teresa Petrucci, Elena Zamagni, Renato Zambello, and Michele Cavo. 2025. "Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers 2025, 17, 1168" Cancers 17, no. 15: 2555. https://doi.org/10.3390/cancers17152555

APA Style

Mancuso, K., Barbato, S., Raimondo, F. D., Gay, F., Musto, P., Offidani, M., Petrucci, M. T., Zamagni, E., Zambello, R., & Cavo, M. (2025). Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers 2025, 17, 1168. Cancers, 17(15), 2555. https://doi.org/10.3390/cancers17152555

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop